SCHEMBL13878077

SCHEMBL13878077

C[C@@H]1C2CC[C@@H](O2)[C@H](C)[C@@]1(O)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15139353 1.00 — —
SCHEMBL23808638 0.91 — —
SCHEMBL15139339 0.91 — —
SCHEMBL13878075 0.91 — —
SCHEMBL23808539 0.90 — —
SCHEMBL13877928 0.89 — —
SCHEMBL15473957 0.87 — —
SCHEMBL23808403 0.87 CSF1R (0.54) —
SCHEMBL19773470 0.87 CSF1R (0.54) —
SCHEMBL23808448 0.87 CSF1R (0.54) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3208269-A1 INHIBITORS OF C-FMS KINASE Janssen Pharmaceutica N.V. (BE) 2017-08-23 — — EP disclosed
EP-2215079-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-12-14 — — EP disclosed
US-8497376-B2 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA N.V. (BE) 2013-07-30 — — US disclosed
US-20090105296-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-23 — — US disclosed
Send feedback